Stephen D Skaper

List of Publications by Year
in descending order

109 papers	6,766 citations	61984 43 h-index	60623 81 g-index
112 all docs	112 docs citations	112 times ranked	8504 citing authors

#	Article	IF	Citations
1	Nerve growth factor: from neurotrophin to neurokine. Trends in Neurosciences, 1996, 19, 514-520.	8.6	650
2	Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. Journal of Neurochemistry, 2001, 77, 94-102.	3.9	353
3	An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Frontiers in Cellular Neuroscience, 2018, 12, 72.	3.7	320
4	The P2X₇purinergic receptor: from physiology to neurological disorders. FASEB Journal, 2010, 24, 337-345.	0.5	305
5	The Neurotrophin Family of Neurotrophic Factors: An Overview. Methods in Molecular Biology, 2012, 846, 1-12.	0.9	295
6	The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors. CNS and Neurological Disorders - Drug Targets, 2008, 7, 46-62.	1.4	276
7	Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB Journal, 2012, 26, 3103-3117.	0.5	221
8	An automated colorimetric microassay for neuronotrophic factors. Developmental Brain Research, 1986, 25, 191-198.	1.7	211
9	Mast cells, glia and neuroinflammation: partners in crime?. Immunology, 2014, 141, 314-327.	4.4	200
10	Melatonin protects against 6â€OHDAâ€induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB Journal, 2001, 15, 164-170.	0.5	187
11	MAPK-activated Protein Kinase 2 Deficiency in Microglia Inhibits Pro-inflammatory Mediator Release and Resultant Neurotoxicity. Journal of Biological Chemistry, 2006, 281, 23658-23667.	3.4	148
12	Nerve growth factor: a neuroimmune crosstalk mediator for all seasons. Immunology, 2017, 151, 1-15.	4.4	141
13	Nerve Growth Factor and Autoimmune Diseases. Autoimmunity, 1994, 19, 141-150.	2.6	129
14	Identification of an N-cadherin Motif That Can Interact with the Fibroblast Growth Factor Receptor and Is Required for Axonal Growth. Journal of Biological Chemistry, 2001, 276, 43879-43886.	3.4	129
15	Neurotrophic Factors: An Overview. Methods in Molecular Biology, 2018, 1727, 1-17.	0.9	124
16	Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator. Molecular Neurobiology, 2013, 48, 340-352.	4.0	110
17	N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. Molecular Neurobiology, 2015, 52, 1034-1042.	4.0	105
18	Neurotrophic Molecules: Strategies for Designing Effective Therapeutic Molecules in Neurodegeneration. Molecular and Cellular Neurosciences, 1998, 12, 179-193.	2.2	98

#	Article	IF	Citations
19	Melatonin maintains glutathione homeostasis in kainic acidâ€exposed rat brain tissues. FASEB Journal, 1997, 11, 1309-1315.	0.5	96
20	Toll-Like Receptors 2, -3 and -4 Prime Microglia but not Astrocytes Across Central Nervous System Regions for ATP-Dependent Interleukin-1Î² Release. Scientific Reports, 2014, 4, 6824.	3.3	96
21	Mast cellâ€“glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3312-3325.	4.0	95
22	Ion Channels on Microglia: Therapeutic Targets for Neuroprotection. CNS and Neurological Disorders - Drug Targets, 2011, 10, 44-56.	1.4	92
23	Inflammatory Mediator Stimulation of Astrocytes and Meningeal Fibroblasts Induces Neuronal Degeneration via the Nitridergic Pathway. Journal of Neurochemistry, 1995, 64, 266-276.	3.9	91
24	Neuroinflammation, Mast Cells, and Glia: Dangerous Liaisons. Neuroscientist, 2017, 23, 478-498.	3.5	87
25	Mast cells differentially express and release active high molecular weight neurotrophins. Molecular Brain Research, 2001, 97, 177-185.	2.3	85
26	P2X7 receptors on microglial cells mediate injury to cortical neurons in vitro. Glia, 2006, 54, 234-242.	4.9	85
27	Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology, 2014, 22, 79-94.	3.9	85
28	Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3193-3200.	4.0	83
29	Excitatory amino acid induced oligodendrocyte cell death inâ€ƒvitro: receptorâ€dependent and â€independent mechanisms. Journal of Neurochemistry, 2004, 90, 1173-1185.	3.9	80
30	Melatonin prevents the delayed death of hippocampal neurons induced by enhanced excitatory neurotransmission and the nitridergic pathway. FASEB Journal, 1998, 12, 725-731.	0.5	78
31	Degenerative Joint Diseases and Neuroinflammation. Pain Practice, 2017, 17, 522-532.	1.9	77
32	Ligand engagement of Toll-like receptors regulates their expression in cortical microglia and astrocytes. Journal of Neuroinflammation, 2015, 12, 244.	7.2	73
33	Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia, 2005, 52, 336-343.	4.9	69
34	Alzheimer's Disease and Amyloid: Culprit or Coincidence?. International Review of Neurobiology, 2012, 102, 277-316.	2.0	67
35	Systematic Review of Pharmacological Properties of the Oligodendrocyte Lineage. Frontiers in Cellular Neuroscience, 2016, 10, 27.	3.7	65
36	Astrocyte-Microglia Cooperation in the Expression of a Pro-Inflammatory Phenotype. CNS and Neurological Disorders - Drug Targets, 2013, 12, 608-618.	1.4	58

#	Article	IF	Citations
37	Potentiation by histamine of synaptically mediated excitotoxicity in cultured hippocampal neurones: a possible role for mast cells. Journal of Neurochemistry, 2008, 76, 47-55.	3.9	56
38	Brain-derived neurotrophic factor selectively rescues mesencephalic dopaminergic neurons from 2,4,5-trihydroxyphenylalanine-induced injury. Journal of Neuroscience Research, 1993, 34, 478-487.	2.9	54
39	Nerve Growth Factor. Molecular Neurobiology, 2001, 24, 183-200.	4.0	53
40	Mast Cell Activation Causes Delayed Neurodegeneration in Mixed Hippocampal Cultures via the Nitric Oxide Pathway. Journal of Neurochemistry, 2002, 66, 1157-1166.	3.9	53
41	Mast cells in chronic inflammation, pelvic pain and depression in women. Gynecological Endocrinology, 2014, 30, 472-477.	1.7	52
42	AÎ²1â€“42 reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: A quantitative analysis. Journal of Neuroscience Methods, 2008, 175, 96-103.	2.5	51
43	Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. NeuroReport, 2003, 14, 1467-1470.	1.2	50
44	Neuronal Growth-Promoting and Inhibitory Cues in Neuroprotection and Neuroregeneration. Annals of the New York Academy of Sciences, 2005, 1053, 376-385.	3.8	49
45	Serum amyloid A primes microglia for ATP-dependent interleukin-1Î² release. Journal of Neuroinflammation, 2018, 15, 164.	7.2	48
46	Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseases. Progress in Brain Research, 2019, 245, 119-144.	1.4	46
47	An automated colorimetric microassay for neuronotrophic factors. Brain Research, 1986, 390, 191-198.	2.2	46
48	Mitogen and stress response kinase-1 (MSK1) mediates excitotoxic induced death of hippocampal neurones. Journal of Neurochemistry, 2004, 86, 25-32.	3.9	42
49	A Pharmacological Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia: A Review. Pain and Therapy, 2018, 7, 59-75.	3.2	42
50	A dimeric version of the short N-cadherin binding motif HAVDI promotes neuronal cell survival by activating an N-cadherin/fibroblast growth factor receptor signalling cascade. Molecular and Cellular Neurosciences, 2004, 26, 17-23.	2.2	40
51	Kainic acid induces selective mitochondrial oxidative phosphorylation enzyme dysfunction in cerebellar granule neurons: protective effects of melatonin and GSH ethyl ester. FASEB Journal, 2001, 15, 1786-1788.	0.5	34
52	Oligodendrocytes are a Novel Source of Amyloid Peptide Generation. Neurochemical Research, 2009, 34, 2243-2250.	3.3	32
53	Culture of Neonatal Rodent Microglia, Astrocytes, and Oligodendrocytes from Cortex and Spinal Cord. Methods in Molecular Biology, 2012, 846, 67-77.	0.9	30
54	Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells. Scientific Reports, 2015, 5, 16676.	3.3	30

#	Article	IF	Citations
55	Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies. Pain and Therapy, 2015, 4, 169-178.	3.2	29
56	Mast Cell - Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications. CNS and Neurological Disorders - Drug Targets, 2016, 15, 1072-1078.	1.4	29
57	Upregulation of death pathway molecules in rat cerebellar granule neurons undergoing apoptosis. Neuroscience Letters, 2001, 302, 113-116.	2.1	28
58	Differences in induction of c-fos transcription by cholera toxin-derived cyclic AMP and Ca2+ signals in astrocytes and 3T3 fibroblasts. Experimental Cell Research, 1991, 194, 210-217.	2.6	27
59	Expression and Differential Responsiveness of Central Nervous System Glial Cell Populations to the Acute Phase Protein Serum Amyloid A. Scientific Reports, 2017, 7, 12158.	3.3	27
60	Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. Journal of Neurochemistry, 2008, 77, 94-102.	3.9	22
61	Impact of Inflammation on the Bloodâ€“Neural Barrier and Bloodâ€“Nerve Interface: From Review to Therapeutic Preview. International Review of Neurobiology, 2017, 137, 29-45.	2.0	22
62	Astrocyte/Microglia Cocultures as a Model to Study Neuroinflammation. Methods in Molecular Biology, 2018, 1727, 127-137.	0.9	22
63	Neuronal Growth-Promoting and Inhibitory Cues in Neuroprotection and Neuroregeneration. Methods in Molecular Biology, 2012, 846, 13-22.	0.9	20
64	TASTPM Mice Expressing Amyloid Precursor Protein and Presenilin-1 Mutant Transgenes Are Sensitive to Î³-Secretase Modulation and Amyloid-Î²₄₂ Lowering by GSM-10h. Neurodegenerative Diseases, 2011, 8, 15-24.	1.4	18
65	Co-Ultramicronized Palmitoylethanolamide/Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells. Molecular Neurobiology, 2018, 55, 103-114.	4.0	18
66	Active Induction of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice. Methods in Molecular Biology, 2018, 1727, 353-360.	0.9	17
67	Intracellular Ion Channel CLIC1: Involvement in Microglia-Mediated Î²-Amyloid Peptide(1-42) Neurotoxicity. Neurochemical Research, 2013, 38, 1801-1808.	3.3	16
68	Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 4-6.	1.4	15
69	Culture of Rodent Cortical, Hippocampal, and Striatal Neurons. Methods in Molecular Biology, 2018, 1727, 39-47.	0.9	15
70	Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy. Progress in Brain Research, 2021, 266, 1-73.	1.4	15
71	MEK inhibition exacerbates ischemic calcium imbalance and neuronal cell death in rat cortical cultures. European Journal of Pharmacology, 2006, 553, 18-27.	3.5	14
72	P2 Receptors in Neurological and Cardiovascular Disorders. Cardiovascular Psychiatry and Neurology, 2009, 2009, 1-13.	0.8	14

#	Article	IF	Citations
73	Culture of Rodent Cortical and Hippocampal Neurons. Methods in Molecular Biology, 2012, 846, 49-56.	0.9	14
74	Isolation and Culture of Rat Cone Photoreceptor Cells. Methods in Molecular Biology, 2012, 846, 147-158.	0.9	11
75	Apoptosis-Associated Tyrosine Kinase and Neuronal Cell Death. Neurochemical Research, 2010, 35, 588-597.	3.3	9
76	Transgenic Mouse Models of Parkinsons Disease and Huntingtons Disease. CNS and Neurological Disorders - Drug Targets, 2010, 9, 455-470.	1.4	9
77	Culture of Neonatal Rodent Microglia, Astrocytes, and Oligodendrocytes from the Cortex, Spinal Cord, and Cerebellum. Methods in Molecular Biology, 2018, 1727, 49-61.	0.9	9
78	Central Nervous System Neuron-Glia Co-culture Models. Methods in Molecular Biology, 2012, 846, 79-89.	0.9	9
79	Receptors as a Transducer in the Co-Occurrence of Neurological/Psychiatric and Cardiovascular Disorders: A Hypothesis. Cardiovascular Psychiatry and Neurology, 2009, 2009, 1-5.	0.8	7
80	Rodent Retinal Ganglion Cell Cultures. Methods in Molecular Biology, 2012, 846, 117-129.	0.9	7
81	Indirect Immunofluorescence Staining of Cultured Neural Cells. Methods in Molecular Biology, 2012, 846, 235-246.	0.9	6
82	Central Nervous System Neuron-Glia co-Culture Models and Application to Neuroprotective Agents. Methods in Molecular Biology, 2018, 1727, 63-80.	0.9	5
83	Compartmented Chambers for Studying Neurotrophic Factor Action. Methods in Molecular Biology, 2012, 846, 213-222.	0.9	5
84	Amyloid Î²-Peptide Neurotoxicity Assay Using Cultured Rat Cortical Neurons. Methods in Molecular Biology, 2012, 846, 57-65.	0.9	5
85	Culture and Characterization of Rat Mesencephalic Dopaminergic Neurons. Methods in Molecular Biology, 2012, 846, 91-101.	0.9	3
86	[3H]Serotonin Release Assay Using Antigen-Stimulated Rat Peritoneal Mast Cells. Methods in Molecular Biology, 2012, 846, 333-341.	0.9	3
87	Commentary: Low-Grade Non-Resolving Neuroinflammation: Age Does Matter. CNS and Neurological Disorders - Drug Targets, 2015, 14, 432-433.	1.4	3
88	Culture of Rat Mesencephalic Dopaminergic Neurons and Application to Neurotoxic and Neuroprotective Agents. Methods in Molecular Biology, 2018, 1727, 107-118.	0.9	2
89	Oligodendrocyte Progenitor Cell Cultures: A Model to Screen Neurotrophic Compounds for Myelin Repair. Methods in Molecular Biology, 2018, 1727, 155-166.	0.9	2
90	Cell Enumeration Assays: Application of the MTT and Sulforhodamine B Assays to Lipopolysaccharide-Stimulated Neonatal Rodent Microglia. Methods in Molecular Biology, 2018, 1727, 167-178.	0.9	2

#	Article	IF	Citations
91	Microglia as a Target for Inflammatory Processes and Neuroprotective Strategies. American Journal of Neuroprotection and Neuroregeneration, 2010, 2, 35-47.	0.1	2
92	Commentary (Research Highlights). CNS and Neurological Disorders - Drug Targets, 2011, 10, 295-295.	1.4	1
93	Commentary((Research Highlights)(Amyotrophic Lateral Sclerosis: Targeting the Bodyâ€™s Energy) Tj ETQq1 1 0.784314 rgBT /Overl	1.4	1
94	(Commentary [Research Highlights] A Toll Road to Alzheimer Disease?). CNS and Neurological Disorders - Drug Targets, 2013, 12, 445-446.	1.4	1
95	Commentary (Research Highlights: TRPV-ing up Pain for a Long Life). CNS and Neurological Disorders - Drug Targets, 2014, 13, 926-926.	1.4	1
96	Mast Cells and Glia as Targets for the Anandamide Congener Palmitoylethanolamide: an Anti-inflammatory and Neuroprotective Lipid Signaling Molecule. , 2017, , 347-369.		1
97	Culture of Purified Glial Cell Populations from Optic Nerve. Methods in Molecular Biology, 2012, 846, 131-145.	0.9	1
98	Culture of Rat Retina Pigmented Epithelial Cells. Methods in Molecular Biology, 2012, 846, 159-166.	0.9	1
99	Glycogen Synthase Kinase 3: Role in Neurodegeneration and Neuroprotection. , 0, , 173-187.		0
100	Commentary (Research Highlights). CNS and Neurological Disorders - Drug Targets, 2011, 10, 1-1.	1.4	0
101	Commentary [Research Highlights (Making Sense Out of Antisense in Huntingtonâ€™s Disease)]. CNS and Neurological Disorders - Drug Targets, 2012, 11, 647-648.	1.4	0
102	Commentary Research Highlights (Amyloid Î²-Peptide and Alzheimerâ€™s Disease: Itâ€™s All the RAGE). CNS and Neurological Disorders - Drug Targets, 2012, 11, 494-494.	1.4	0
103	Commentary Research Highlights (Amyloid and Alzheimer's Disease: Easing the Load). CNS and Neurological Disorders - Drug Targets, 2012, 11, 4-4.	1.4	0
104	Commentary. CNS and Neurological Disorders - Drug Targets, 2012, 11, 192-192.	1.4	0
105	Commentary Research Highlights (Purines, Pores and Pain: Is it in Our Genes?). CNS and Neurological Disorders - Drug Targets, 2012, 11, 335-335.	1.4	0
106	Commentary (Research Highlights: WNT-erizing Against Neuropathic Pain). CNS and Neurological Disorders - Drug Targets, 2014, 13, 191-191.	1.4	0
107	Reply to: â€œPalmitoylethanolamide: problems regarding micronization, ultra-micronization and additivesâ€•Inflammopharmacology DOI:10.1007/s10787-014-0202-3. Inflammopharmacology, 2015, 23, 127-130.	3.9	0
108	Commentary: Fatal French Clinical Trial: What Can We Learn from What Went Wrong?. CNS and Neurological Disorders - Drug Targets, 2016, 15, 752-753.	1.4	0

#	Article	IF	Citations
109	Meet Our Editor-in-Chief. CNS and Neurological Disorders - Drug Targets, 2017, 16, .	1.4	0